CA
NZ
UK
AU
IND
US
Market capitalization sits at roughly $325 million, while the 52‑week price band stretches from $1.33 to $2.53. The result validates investor optimism surrounding the company’s PAH program and fuels further price momentum.
LENZ Therapeutics reported a Q2 loss but managed to exceed revenue expectations, beating estimates by $0.05 per share. The company's performance has sparked a substantial rally in its stock, as heightened investor sentiment reflects confidence in its growth trajectory. The market's positive reception illustrates …
The study, involving 1,465 men across 51 clinical sites in the U.S. and Europe, indicates both safety and tolerability comparable to traditional treatments. The finding has generated significant interest as male androgenetic alopecia, which affects approximately 40% of men globally, presents a substantial market …
This patent focuses on the delivery of nicotine, vitamins, and caffeine in various forms including dissolvable strips, gum, and lozenges. The approval not only secures CTT’s innovations but potentially opens newRevenuestreams in the growing pharmaceutical space. This strategic advancement could play a important role …
Intermountain Health has expanded access to the investigational drug daraxonrasib for patients battling advanced pancreatic cancer across ten hospitals in Utah, Colorado, and Montana. This groundbreaking initiative aims to provide eligible patients with a new treatment option that has demonstrated a remarkable ability to …
Definium Secures Second Regulatory Endorsement for LSD Therapy
Definium Therapeutics, Inc. (NASDAQ: DFTX) reported groundbreaking results from its Phase 3 Voyage study of DT120 ODT, a treatment for generalized anxiety disorder (GAD). The primary endpoint showed a strong 5.4-point reduction on the Hamilton Anxiety Rating Scale (HAM-A) compared to placebo, with results …
Dyadic International, Inc. (NASDAQ: DYAI) released its financial results for the quarter ending June 30, 2026, showing a net loss of $2,123,884. Revenue for the period was $961,138, lower than the $966,630 reported a year earlier. The decline in revenue was partially offset by …
Eli Lilly and Co (NYSE: LLY). is taking legal action against six pharmacies and peptide vendors for allegedly selling unauthorized versions of retatrutide, the company's next major weight-loss drug. This lawsuit targets firms selling compounded versions of the medication without approval, jeopardizing Eli Lilly's …
The company also postedEarnings Per Shareof $-14.41, comfortably beating the consensus estimate of $-22.10.
Please wait processing your request...